Monday, March 17, 2025 | 12:53 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Lupin launches Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

Image

Capital Market
Lupin announced the launch of Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg, having received an approval from the United States Food and Drug Administration (FDA).

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg, are the generic equivalent of Truvada Tablets 200 mg/300 mg, of Gilead Sciences, Inc., and indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets (RLD: Truvada) had estimated annual sales of USD 2.1 billion in the U.S. (IQVIA MAT March 2021).

 

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 25 2021 | 8:05 PM IST

Explore News